Silo believes that SPC-14 should be eligible for development under the FDA’s 505(b)(2) regulatory pathway.
Silo Pharma said it has exercised its option to license SPC-14, a therapeutic for the treatment of Alzheimer’s disease, from Columbia University.
The deal is “pursuant to a sponsored research and option agreement established in 2021,” according to the company.
Under the terms of the license agreement, Silo will be granted an exclusive license to further develop, manufacture and commercialize SPC-14 worldwide upon consummation of the agreement.
The company said expects to finalize and enter into the exclusive license agreement in the first half of this year.
“Columbia University has discovered a therapeutic candidate that could bring relief and hope for Alzheimer’s patients and families,” said Eric Weisblum, CEO of Silo Pharma. “In our opinion, available treatments for AD remain largely inadequate. We believe that the cognitive improvement and stress reduction shown by SPC-14 in preclinical studies could hold promise for this underserved disease market.”
Sarasota, Florida-based Silo is a developmental-stage biopharmaceutical company “focused on developing novel formulations and drug-delivery systems for traditional therapeutics and psychedelic treatments.”
The global market for Alzheimer’s disease therapeutics is forecasted to exceed $30.8 billion by 2033, with a compound annual growth rate of 18.8% from 2024 to 2033, according to Market.us. Rising prevalence of the disease in the expanding elderly population and advancements in neurological research are expected to drive market growth.
Silo said it believes that SPC-14 should be eligible for development under the FDA’s 505(b)(2) regulatory pathway.